No Data
No Data
Avidity Biosciences: Advancing Clinical Programs With Strategic Focus and Growth Potential
Dyne, Avidity Initiated at Outperform by RBC on DM1 Drugs
Avidity Biosciences to Participate in Upcoming Investor Conference
RBC Initiates Avidity Biosciences at Outperform, Speculative Risk With $67 Price Target
RBC Capital Initiates Avidity Biosciences(RNA.US) With Buy Rating, Announces Target Price $67
Express News | Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
No Data
No Data